Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1

Conditions

Urinary Bladder Neoplasms 40Carcinoma, Transitional Cell 3Muscle Invasive Bladder Cancer 2Infiltrating Bladder Urothelial Carcinoma 2Carcinoma, Renal Cell 2Urologic Neoplasms 1Urologic Diseases 1Urinary Bladder Diseases 1Ureteral Neoplasms 1Transitional Cell Carcinoma of the Bladder 1Transitional Cell Bladder Cancer 1Stage 0is Bladder Urothelial Carcinoma 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Non-metastatic Muscle Invasive Bladder Cancer 1Invasive Bladder Cancer 1Ileus 1Cone Dystrophy 3 1Bladder Adenocarcinoma 1Adrenal Gland Neoplasms 1

Interventions

durvalumab 1Vinblastine 1Methotrexate 1Gemcitabine 1Doxorubicin 1Cystectomy 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Bladder Adenocarcinoma × Cystectomy × Clear all
NCT03912818 2023-09-11

Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

Stanford University

Phase 2 Terminated
7 enrolled 9 charts
GenitourinarySarcoma

Bladder Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡